These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11597010)

  • 1. Palpable breast cancers are inherently different from nonpalpable breast cancers.
    Skinner KA; Silberman H; Sposto R; Silverstein MJ
    Ann Surg Oncol; 2001 Oct; 8(9):705-10. PubMed ID: 11597010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between palpable and nonpalpable tumors in early-stage, hormone receptor-positive breast cancer.
    Warren SL; Bhutiani N; Agle SC; Martin RCG; McMasters KM; Ajkay N
    Am J Surg; 2018 Aug; 216(2):326-330. PubMed ID: 29502856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability.
    Silverstein MJ; Gierson ED; Waisman JR; Colburn WJ; Gamagami P
    J Am Coll Surg; 1995 Jun; 180(6):700-4. PubMed ID: 7773483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpalpable versus palpable invasive breast tumors treated with breast-conserving surgical management.
    Tafra L; Essner R; Brenner RJ; Giuliano AE
    Am Surg; 1996 May; 62(5):395-9. PubMed ID: 8615571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of palpable and nonpalpable breast cancers.
    Pagana TJ; Lubbe WJ; Schwartz SM; Sprechini GD
    Arch Surg; 1989 Jan; 124(1):26-8. PubMed ID: 2910245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
    Geary ES; Stamey TA
    J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting axillary nodal positivity in 2282 patients with breast carcinoma.
    Silverstein MJ; Skinner KA; Lomis TJ
    World J Surg; 2001 Jun; 25(6):767-72. PubMed ID: 11376414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer after augmentation mammoplasty.
    Skinner KA; Silberman H; Dougherty W; Gamagami P; Waisman J; Sposto R; Silverstein MJ
    Ann Surg Oncol; 2001 Mar; 8(2):138-44. PubMed ID: 11258778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from a multidisciplinary breast center. Analysis of disease discovered.
    Silverstein MJ; Gamagami P; Masetti R; Legmann MD; Craig PH; Gierson ED
    Surg Oncol Clin N Am; 1997 Apr; 6(2):301-14. PubMed ID: 9115497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
    Barth A; Craig PH; Silverstein MJ
    Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass index influences palpability but not stage of breast cancer at diagnosis.
    Chagpar AB; McMasters KM; Saul J; Nurko J; Martin RC; Scoggins CR; Edwards MJ
    Am Surg; 2007 Jun; 73(6):555-60; discussion 560. PubMed ID: 17658091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Mamtani A; Patil S; Stempel MM; Morrow M
    Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with breast cancer: differences in color Doppler flow and gray-scale US features of benign and malignant axillary lymph nodes.
    Yang WT; Chang J; Metreweli C
    Radiology; 2000 May; 215(2):568-73. PubMed ID: 10796941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology of HER 2 positive small invasive (T1a,b) breast cancer: "A wolf in sheep's clothing".
    Bezić J; Šamija Projić I; Projić P; Meljanac Salopek K; Živković PM; Božić J; Tomić S
    Pathol Res Pract; 2017 Dec; 213(12):1510-1514. PubMed ID: 29033181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting surgical margins in nonpalpable breast tumors excised with the radioguided occult lesion localization approach.
    Vernet-Tomas Mdel M; Ortega M; Vidal S; Corominas JM; Carreras R
    J Obstet Gynaecol Res; 2011 May; 37(5):422-7. PubMed ID: 21272155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
    Ohori M; Wheeler TM; Scardino PT
    Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.
    Vasconcelos I; Hussainzada A; Berger S; Fietze E; Linke J; Siedentopf F; Schoenegg W
    Breast; 2016 Oct; 29():181-5. PubMed ID: 27544822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma.
    Voit CA; van Akkooi AC; Eggermont AM; Schäfer-Hesterberg G; Kron M; Ulrich J; Sterry W; Schoengen A; Rademaker J
    J Natl Cancer Inst; 2011 Dec; 103(23):1771-7. PubMed ID: 21940673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.
    Kumar R; Jana S; Heiba SI; Dakhel M; Axelrod D; Siegel B; Bernik S; Mills C; Wallack M; Abdel-Dayem HM
    J Nucl Med; 2003 Jan; 44(1):7-10. PubMed ID: 12515869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.